We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App

Microarray-Based COVID-19 Test Analyzes Sample in Triplicate for Each Patient Swab Within Each Array For 100% Specificity

By LabMedica International staff writers
Posted on 22 Jul 2021
Print article
Image: DetectX-Rv Microarray Assay (Photo courtesy of PathogenDx, Inc.)
Image: DetectX-Rv Microarray Assay (Photo courtesy of PathogenDx, Inc.)
A low-cost, high-throughput microarray-based test ensures 100% specificity by analyzing the sample in triplicate for each patient swab within each array, as compared to just once by COVID-19 tests that are currently approved.

PathogenDx, Inc. (Scottsdale, AZ, USA) has received the CE-IVD Mark for the sale and distribution of its patented DetectX-Rv Microarray Assay for COVID-19 testing across Europe. PathogenDx's DetectX-Rv microarray utilizes nasopharyngeal swabs and nasal aspirate or fluid to detect SARS-CoV2 within three hours after RNA extraction, and has received Emergency Use Authorization (EUA) from the US Food and Drug Administration (FDA). Its multiplex system also has the capability of pooled sample testing for the detection of SARS-CoV2 in multiple samples at one time, dramatically increasing COVID-19 testing throughput.

DetectX-Rv delivers superior accuracy based on its proprietary technology of analyzing dozens of probes in COVID-19 regions of the viral genome, delivering a Limit of Detection of 1,000 copies/mL. The test also ensures 100% specificity by analyzing the sample in triplicate for each patient swab within each array, not just once as conducted in currently approved COVID-19 tests.

"Receiving the CE-IVD Mark for our DetectX-Rv test is a massive milestone for our company and will not only help detect COVID-19 in Europe as the pandemic sweeps on, but with the company's follow-on Detect-Cv Clade variant test helps identify the Variant of Concern and/or Variant of Interest from any positive result processed either from DetectX-Rv or any other molecular platform," said Milan Patel, Co-founder and CEO of PathogenDx. "Although we are in the second year of the pandemic and vaccine distribution has greatly improved, COVID-19 and its variants persist in our global community. The virus will continue to mutate and we need to be able to identify if an infected patient has a particular variant in order to provide the most effective clinical and therapeutic treatment. Global distribution of diagnostic tests like our DetectX-Rv test is crucial in helping limit the spread of COVID-19 and its variants."

Related Links:
PathogenDx, Inc.

Gold Supplier
Next-Generation Sequencing Platform
Clear Dx
Silver Supplier
Cartridge Incubator
WS-i60 Cartridge Incubator
Laboratory Management Software

Print article


Clinical Chem.

view channel
VIASURE HLA Celiac Real Time PCR Detection Kit

CerTest VIASURE HLA Celiac RT PCR Kit Enables Rapid Resolution of HLA Haplotypes Associated with Celiac Disease

CerTest Biotec (Zaragoza, Spain) has developed a simple and ready to use real-time PCR for the detection of the principal alleles of the HLA system and the subsequent determination of the DQ2 and DQ8 antigens... Read more


view channel

First-Of-Its Kind Blood Test to Distinguish between Bacterial and Viral Infections Using Body’s Immune Response Granted FDA Clearance

A first-of-its kind test that decodes the immune response to accurately distinguish between bacterial or viral infections within minutes has been granted clearance by the US Food and Drug Administration (FDA).... Read more


view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Thermo Fisher Launches World’s First Fully Integrated Digital PCR (dPCR) System

Thermo Fisher Scientific Inc. (Waltham, MA, USA) has launched the world’s first fully integrated digital PCR (dPCR) system designed to provide highly accurate and consistent results within 90 minutes.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.